Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Reaffirmed by BTIG Research
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “buy” rating reissued by BTIG Research in a research report issued to clients and investors on Monday, MarketBeat.com reports. They presently have a $4.00 price objective on the biopharmaceutical company’s stock. BTIG Research’s target price suggests a potential upside of 207.69% from the stock’s current […]
2 Oct 05:28 · The Markets Daily